3D Medicines Inc Sustainability Reports
The company is a clinical-stage biopharmaceutical enterprise focused on the development and commercialization of oncology immunotherapies. Its primary products include subcutaneously-injectable PD-L1 inhibitors designed to help cancer patients live longer and better.
Sector: Manufacturing
Country: China
Exchange: Hong Kong Stock Exchange
FIGI: BBG01BTDDZN7
8 reports from 2022 to 2025
